- Home
- BMEA
BMEA
Biomea Fusion Inc.
as 12-20-2024 3:32pm EST
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 153.3M | IPO Year: | 2021 |
| Target Price: | $37.25 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $20.21 | Next Earning Date: | 10-29-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Biomea Fusion Inc. (BMEA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hitchcock Michael J.M. | BMEA | Director | Sep 30 '24 | Buy | $10.06 | 10,000 | $100,600.00 | 15,000 |
Latest Biomea Fusion Inc. News
BMEA Breaking Stock News: Dive into BMEA Ticker-Specific Updates for Smart Investing
Benzinga
5 days ago
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
GlobeNewswire
5 days ago
Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
GlobeNewswire
5 days ago
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
GlobeNewswire
9 days ago
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
MT Newswires
12 days ago
Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours
GlobeNewswire
13 days ago
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
GlobeNewswire
16 days ago
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
GlobeNewswire
20 days ago
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
Compare BMEA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BMEA Biomea Fusion Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.